申请人:TAKEDA PHARMACEUTICAL COMPANY LIMITED
公开号:US09434743B2
公开(公告)日:2016-09-06
Disclosed are compounds of Formula 1,
and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, and R6 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating obesity and related diseases, disorders, and conditions associated with MetAP2.
本发明涉及1号式化合物及其药学上可接受的盐,其中R1、R2、R3、R4、R5和R6在规范中定义。本公开还涉及制备1号式化合物的材料和方法,包括含有它们的制药组合物,并且涉及使用它们治疗肥胖和与MetAP2相关的疾病、障碍和状况。